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Introduction 
Chlamydia trachomatis is an obligate intracellular 
microorganism responsible for several diseases. It is 
considered the most common bacterial sexually 
transmitted infection (STI) worldwide. The World 
Health Organization (WHO) estimates that 92 million 
new cases of C. trachomatis occur globally every year. 
An estimated 3 to 4 million new cases are diagnosed 
every year in the United States, 5 million in Western 
Europe, and 16 million in sub-Saharan Africa [1]. 
According to estimates from the Centers for Disease 
Control and Prevention (CDC), 75% of new cases in 
the United States are diagnosed in asymptomatic 
women. The sequelae of chlamydial infection in 
women are severe and can lead to serious 
complications, including pelvic inflammatory disease, 
ectopic pregnancy, infertility, and chronic pelvic pain 
[2,3]. Chlamydial genital infections have also been 
reported to increase human immunodeficiency virus 
transmission and influence the development of human 
papillomavirus-induced adenocarcinoma [4,5,6]. In 
addition, pregnant women infected with C. 
trachomatis put their children at risk for conjunctivitis 
and pneumonitis through mother-to-child transmission 
[7]. In men C. trachomatis is associated with non-
gonococcal urethritis and epididymitis [8]. In the male 
high-risk group, 50% are asymptomatic with mild 
symptoms. 
Today, sexually transmitted diseases are major and 
ever-expanding public health and social problems 
because of an increased rate of C. trachomatis  
 
infection in both the female and male population 
within the sexually active 20- to 30-year-old group 
[9,10,11]. Several hypotheses may explain the rise of 
chlamydial infections, including changes in sexual 
behavior and insufficient knowledge of sexual life and 
sexual health. Moreover, the use of more sensitive 
tests may contribute to the rising rates. In Northern 
Sardinia as well, the problem is rising among young 
people [12]. For this reason, screening programs must 
be implemented to prevent morbidity. Furthermore, a 
rapid diagnosis of the microorganism is essential to 




The objective of this study was to compare two 
methods for the detection of C. trachomatis: the BD 
ProbeTec ET System (Becton Dickinson, Franklin 
Lakes, United States), performed according to the 
manufacturer’s instructions, versus an in-house one 
tube nested PCR performed as previously published 
[13]. The BD ProbeTec ET System is the first real-
time DNA amplification assay for the detection of C. 
trachomatis; it is a rapid test that can be used to screen 
extragenital as well genital specimens.  
In this study we evaluated a total of 511 samples 
collected in one year from both male (aged 20 to 65 
years) and female (aged 15 to 35 years) patients with 
suspected sexually transmitted infections as follows: 
330 cervical swabs, 34 vaginal swabs, 94 semen 
samples, 35 urine samples, 7 urethral swabs, 6 
conjuntival swabs and 5 samples from other body 
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areas. According to Italian law informed consent was 
not necessary. 
 
C. trachomatis detection in female samples  
Of the 330 cervical swab specimens tested, 11 
(3.3%) were positive by the BD ProbeTec ET System, 
while 10 (3%) were positive by the nested PCR. Of the 
34 vaginal swabs only one was positive by the BD 
ProbeTec ET System, but no sample was positive by 
the nested PCR. Of the 16 urine samples, 5 were 
positive by the BD ProbeTec ET System, and only two 
were positive by the nested PCR. One sample of pus 
was positive by both methods. 
 
C. trachomatis detection in male samples 
A total of 126 samples were tested. Of the 94 
semen samples tested, only one was positive by the 
BD ProbeTec ET System but negative by the nested 
PCR. Eleven samples were indeterminate using the 
BD ProbeTec ET System; these were repeated and 
resulted negative. The other male samples were all 
negative. 
Regarding the prevalence of C. trachomatis in 
non-pregnant women, Adams [14] published a review 
study in which the prevalence was stratified by age. 
The highest prevalence was observed in the under 20-
year-old age group with 8.1%, declining up to 1.4% in 
those aged over 30 years.  
In our study, we found 12 positive samples in 
endocervical swabs out of 280 from women aged 
between 20 to 30 years and 5 positive out of 13 in 
urine samples. Furthermore, we analyzed 23 
endocervical swabs from pregnant patients. We 
obtained 14 (61%) positive samples using the BD 
ProbeTec ET System and 13 (56%) positive samples 
by nested PCR. Other samples from a group of 20- to 
35-year-old patients were negative. 
The sensitivity, specificity, positive and negative 
predictive values (PPV and NPV) were 95%, 100%, 
100% and 99% for the BD ProbeTec ET System and 
65%, 100%, 100%, and 98% respectively, for the 
nested PCR method. 
We observed a good agreement between the two 
systems for detection of C. trachomatis. Concordance 
was high (0.988) between the two assays, and the 
degree of agreement kappa (k = 0.807) was very good. 
 
Conclusions 
An infection with C. trachomatis is characterized 
as a colonization of the cervix or urethra, independent 
of clinical symptoms [15]. The estimated prevalence 
of infected sexually active women varies worldwide 
from 2.2% to above 20% in high-risk populations, 
with different percentages based on age and ethnicity 
within the same country [16]. The reported prevalence 
varies widely, but most commonly reported infection 
rates ranged between 4% and 6% among European 
non-pregnant women [17]. 
Our study involved a large and representative 
group of young women; the age shift prevalence 
among young women observed in our study has also 
been highlighted by research groups worldwide in 
various populations. This concordance confirms the 
importance of screening for chlamydial infections to 
control asymptomatic/latent sexually transmitted 
diseases and to correctly diagnose the disease, which 
may have overlapping signs and symptoms patterns 
with other diseases. Women aged under 25 years 
should be the target of a C. trachomatis screening 
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